Flunixin + Oxytetracycline
12 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 12 |
| Reports involving death | 4 |
| Case-fatality rate (reported events) | 3330.0% |
| Distinct species in reports | 4 |
| Distinct breeds in reports | 6 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 2 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Flunixin + Oxytetracycline Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 12 adverse event reports referencing Flunixin + Oxytetracycline, including 4 reports in which the animal died — a 3330.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Flunixin, Oxytetracycline. Reported administration routes include Subcutaneous, Unknown, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Flunixin + Oxytetracycline reports are Cattle (8 reports), Human (2 reports), Sheep (1 reports), with Cattle accounting for the largest share. Within those species, Unknown (4), Aberdeen Angus (3), Holstein-Friesian also known as Holstein (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Flunixin + Oxytetracycline are Death (3), Injection site swelling (3), Accidental exposure (2), Anaphylaxis (2). Of the 11 reports with a coded outcome, Ongoing is the leading category at 36.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Flunixin + Oxytetracycline.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.